CD44 and breast carcinoma: Similarly, Hong and colleagues found that FH535, another β-catenin/TCF inhibitor, significantly suppressed tumor sphere formation and the CD44+/CD24− BCSC subpopulation in mouse breast cancer cells (Jang et al., 2015a).